(CS) AXA - Overview
Stock: Insurance, Asset Management, Banking, Reinsurance, Health Protection
Dividends
| Dividend Yield | 5.23% |
| Yield on Cost 5y | 15.69% |
| Yield CAGR 5y | 10.73% |
| Payout Consistency | 95.6% |
| Payout Ratio | 65.4% |
| Risk 5d forecast | |
|---|---|
| Volatility | 16.4% |
| Relative Tail Risk | 4.84% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.35 |
| Alpha | 4.75 |
| Character TTM | |
|---|---|
| Beta | 0.030 |
| Beta Downside | 0.181 |
| Drawdowns 3y | |
|---|---|
| Max DD | 13.92% |
| CAGR/Max DD | 1.30 |
Description: CS AXA January 27, 2026
AXA SA (ticker CS) is a global insurer and asset manager headquartered in Paris, operating through six geographic and functional segments: France, Europe, AXA XL, Asia, Africa & EME-LATAM, AXA Investment Managers, plus a Transversal & Other unit. Its product suite spans life and savings policies, property-and-casualty cover, specialty reinsurance (e.g., environmental liability, marine, aviation), digital health services, travel assistance, parametric insurance, and a mobility virtual-payment card, while its asset-management arm delivers multi-manager solutions across major asset classes.
In FY 2023 AXA reported €156 billion in total revenues, a net profit of €5.5 billion and a combined ratio of 94.3 % in its Property-Casualty business, reflecting continued underwriting discipline. The firm’s solvency II ratio stood at 226 %, well above the regulatory minimum, and its return on equity (ROE) improved to 9.8 % versus 8.5 % the prior year. Key sector drivers include the low-interest-rate environment pressuring investment income, heightened climate-risk exposure prompting growth in specialty reinsurance, and accelerated digital transformation of claims and health services.
For a deeper dive into AXA’s valuation dynamics and scenario-based risk assessments, consider exploring the analytical tools available on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 13.00b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 2.73 > 1.0 |
| NWC/Revenue: 210.0% < 20% (prev -130.9%; Δ 340.9% < -1%) |
| CFO/TA 0.04 > 3% & CFO 28.20b > Net Income 13.00b |
| Net Debt (42.87b) to EBITDA (20.25b): 2.12 < 3 |
| Current Ratio: 24.30 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.16b) vs 12m ago -3.78% < -2% |
| Gross Margin: 108.8% > 18% (prev 0.95%; Δ 10.8k% > 0.5%) |
| Asset Turnover: 24.48% > 50% (prev 21.31%; Δ 3.17% > 0%) |
| Interest Coverage Ratio: 12.67 > 6 (EBITDA TTM 20.25b / Interest Expense TTM 1.21b) |
Altman Z'' 3.77
| A: 0.51 (Total Current Assets 343.47b - Total Current Liabilities 14.14b) / Total Assets 645.57b |
| B: 0.06 (Retained Earnings 35.58b / Total Assets 645.57b) |
| C: 0.02 (EBIT TTM 15.32b / Avg Total Assets 640.57b) |
| D: 0.08 (Book Value of Equity 45.49b / Total Liabilities 588.98b) |
| Altman-Z'' Score: 3.77 = AA |
Beneish M -3.34
| DSRI: 0.70 (Receivables 9.90b/12.17b, Revenue 156.81b/135.46b) |
| GMI: 0.87 (GM 108.8% / 94.50%) |
| AQI: 0.93 (AQ_t 0.46 / AQ_t-1 0.50) |
| SGI: 1.16 (Revenue 156.81b / 135.46b) |
| TATA: -0.02 (NI 13.00b - CFO 28.20b) / TA 645.57b) |
| Beneish M-Score: -3.34 (Cap -4..+1) = AA |
What is the price of CS shares?
Over the past week, the price has changed by +1.88%, over one month by -6.61%, over three months by -2.34% and over the past year by +10.32%.
Is CS a buy, sell or hold?
What are the forecasts/targets for the CS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 45.1 | 17.3% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 46.5 | 21% |
CS Fundamental Data Overview January 28, 2026
P/E Trailing = 11.5228
P/E Forward = 9.8232
P/S = 0.8503
P/B = 1.733
P/EG = 1.2122
Revenue TTM = 156.81b EUR
EBIT TTM = 15.32b EUR
EBITDA TTM = 20.25b EUR
Long Term Debt = 29.54b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.27b EUR (from shortTermDebt, last fiscal year)
Debt = 65.32b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 42.87b EUR (from netDebt column, last quarter)
Enterprise Value = 122.12b EUR (79.26b + Debt 65.32b - CCE 22.45b)
Interest Coverage Ratio = 12.67 (Ebit TTM 15.32b / Interest Expense TTM 1.21b)
EV/FCF = 4.48x (Enterprise Value 122.12b / FCF TTM 27.26b)
FCF Yield = 22.32% (FCF TTM 27.26b / Enterprise Value 122.12b)
FCF Margin = 17.38% (FCF TTM 27.26b / Revenue TTM 156.81b)
Net Margin = 8.29% (Net Income TTM 13.00b / Revenue TTM 156.81b)
Gross Margin = 108.8% ((Revenue TTM 156.81b - Cost of Revenue TTM -13.79b) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 79.43%)
Tobins Q-Ratio = 0.19 (Enterprise Value 122.12b / Total Assets 645.57b)
Interest Expense / Debt = 0.46% (Interest Expense 299.0m / Debt 65.32b)
Taxrate = 25.32% (659.5m / 2.60b)
NOPAT = 11.44b (EBIT 15.32b * (1 - 25.32%))
Current Ratio = 24.30 (Total Current Assets 343.47b / Total Current Liabilities 14.14b)
Debt / Equity = 1.44 (Debt 65.32b / totalStockholderEquity, last quarter 45.49b)
Debt / EBITDA = 2.12 (Net Debt 42.87b / EBITDA 20.25b)
Debt / FCF = 1.57 (Net Debt 42.87b / FCF TTM 27.26b)
Total Stockholder Equity = 45.27b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.03% (Net Income 13.00b / Total Assets 645.57b)
RoE = 28.73% (Net Income TTM 13.00b / Total Stockholder Equity 45.27b)
RoCE = 20.48% (EBIT 15.32b / Capital Employed (Equity 45.27b + L.T.Debt 29.54b))
RoIC = 9.92% (NOPAT 11.44b / Invested Capital 115.36b)
WACC = 3.45% (E(79.26b)/V(144.58b) * Re(6.02%) + D(65.32b)/V(144.58b) * Rd(0.46%) * (1-Tc(0.25)))
Discount Rate = 6.02% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.49%
[DCF Debug] Terminal Value 87.94% ; FCFF base≈20.15b ; Y1≈23.56b ; Y5≈35.43b
Fair Price DCF = 475.8 (EV 1037.49b - Net Debt 42.87b = Equity 994.62b / Shares 2.09b; r=5.90% [WACC]; 5y FCF grow 17.97% → 2.90% )
EPS Correlation: -4.58 | EPS CAGR: -58.16% | SUE: 0.0 | # QB: 0
Revenue Correlation: -26.53 | Revenue CAGR: -27.36% | SUE: -0.72 | # QB: 0
EPS next Year (2026-12-31): EPS=4.16 | Chg30d=+0.015 | Revisions Net=+4 | Growth EPS=+7.1% | Growth Revenue=+4.5%